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ABSTRACT Cyanogen bromide cleavage of the heavy
(alpha) chain of protein 315 (an immunoglobulin A mouse
myeloma protein with anti-dinitrophenyl activity) yielded
five fragments of which one (CN2), with 156 residues,
contained the chain's entire variable region. Determina-
tion of the amino-acid sequence of CN2 showed that:
(1) the variable region has appreciable homology (about
33% identities) with the variable region of the light
chain from the same molecule; and (2) the constant-
region sequence immediately following the probable
transition from variable to constant domains is the same
in the protein-315 a as in human -yl and p chains (-Val-
Ser- Ser-). The sequence of the cyanogen bromide octa-
peptide (CN5) from the carboxy terminus of the protein-
315 heavy chain closely resembles the corresponding seg-
ments ofhuman a and ju chains.
Multiple lines of evidence show that the ligand-binding speci-
ficities of antibody molecules are determined by about 107
residues at the amino terminus of light chains and about 115
at the amino terminus of heavy chains (called VL and VH
regions, respectively) (1-3). The complete amino-acid se-
quences for VL and VH of the same molecule have been esta-
blished for two myeloma proteins (4-6), but their ligand-
binding specificities are not known.
The purpose of this paper is to report the amino-acid se-
quence of the variable region of the heavy chain (H315) from
protein 315. This sequence and that previously reported for
the light chain from the same molecule (7) provide an es-
sentially complete primary structure for the VH and VL regions
of protein 315. The results are of particular interest because
this protein, an IgA myeloma protein produced by mouse
plasmacytoma MOPC-315, is known to have ligand-binding
sites that resemble in many ways those of antibodies against
Dnp and Tnp raised by conventional immunization procedures
(8). For instance, protein 315 binds Dnp and Tnp ligands with
high affinity, distinguishes sharply among ligands of similar
structure (e.g., between 2, and 2,6-Dnp groups), and ex-
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hibits several of the characteristic spectral changes undergone
by ligand and immunoglobulin in the immune complex. In
addition, the specific-binding reactions of protein 315 are
enthalpy-driven and show the same "strange" crossreactions
between Dnp, 5-acetouracil, and menadione (2-methyl-1,4-
naphthoquinone; vitamin K3) that are also found with many
conventionally raised antibodies against Dnp (8).
Protein 315 was purified from serum of BALB/c mice
bearing the MOPC-315 tumor, and its fully reduced, amino-
ethylated chains were isolated as described (9). The frag-
ments obtained from cyanogen bromide degradation of the
heavy chain were subjected to sequence analysis in the Beck-
man sequenator and by the dansyl-Edman procedure (10, 11).
Several of the fragments were degraded further with trypsin,
chymotrypsin, and thermolysin into smaller peptides, which
were purified by ion exchange chromatography on Dowex resins
(12), gel filtration, paper chromatography, and high-voltage
electrophoresis. The amino-acid sequences of these peptides
were determined with the aid of dansyl-Edman degradation
and by digestion with carboxypeptidases A and B. Analysis of
heavy chains from intact molecules that had been labeled
with a specific affinity-labeling reagent ([14C]bromoacetyl-
Dnp-L-lysine) aided in identification of the fragment with the
variable region (13).
Cyanogen bromide cleavage of the fully reduced, amino-
ethylated heavy chain yielded five fragments that were
purified largely by gel filtration on Sephadex (G-50 and G-100)
in 5 M guanidine- HCl (Fig. 1). This report focuses on the
2nd and 5th fragments, CN2 and CN5, which correspond,
respectively, to a large amino-terminal (variable) segment and
a small carboxy-terminal (constant) segment of the chain.
The other fragments, all derived from within the constant
region, will be described elsewhere: here we note only that
CN1 has approximately 228 residues, CN3 is a mixture of
peptides, including one with carbohydrate, and CN4 is an
octapeptide.
CN2 contains the entire VH region and the adjoining por-
tion of the constant region, including the latter's first Cys
peptide. It has 156 amino-acid residues and lacks carbohy-
drate. End-group analysis by the cyanate (R. A. Bradshaw,
unpublished results) and methylisothiocyanate (10) pro-
cedures showed that the amino-terminal residue in both this
fragment and in the intact heavy chain is aspartic acid.
When the whole chain and CN2 were analyzed with the Beck-
man automatic sequenator, it was possible to identify the
first nine residues of the chain and the first 49 of the frag-
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FIG. 1. Elution profile of the cyanogen bromide fragments of the heavy chain of protein 315. Heavy chain (7 mg) was cleaved with
CNBr (CNBr/protein, 5/1, w/w) in 70% formic acid for 24 hr at 40, and then placed on Sephadex G-100 (1.0 X 110 cm) in 5 M guani-
dine HCl (Mann, Ultrapure) at a flow rate of about 5 ml/hr. 1.0-ml fractions were collected per tube. Volume markers are immuno-
globulin light chain (L), molecular weight about 22,000, and lysozyme (Ly'zme), molecular weight 13,000; Vo, void volumes.
ment: both sequences were in complete agreement. Finally,
when the affinity-labeled heavy chain (with [14C]bromoacetyl-
Dnp-L-lysine) was cleaved with cyanogen bromide and the
fragments were separated as in Fig. 1, only CN2 contained
the 14C label; the label is known to attach to a lysine residue
that, by homology with other VH sequences, was previously
localized in the VH region (13).
CN2 was reacted with maleic anhydride and then digested
with trypsin (14). The resulting arginine peptides, purified by
ion exchange chromatography and gel filtration, accounted
for the entire fragment. These peptides were subjected to
sequence analysis and then aligned with the aid of other
peptides derived from thermolytic and chymotryptic cleav-
ages of CN2. The sequence from positions 1 to 156 is com-
pared in Fig. 2 with the heavy chain of mouse protein 173 (an
IgG myeloma protein produced by plasmacystoma MOPC-
173) and with human heavy chains of various classes and VH
subgroups (4-6, 15, 16). The sequence from positions 38 to 67
in H315 corresponds to the affinity-labeled [14C]bromoacetyl-
Dnp-rlysine peptide previously reported by Haimovich et al.;
lysine 52 is the specifically labeled residue (13).
VH of protein 315 resembles other VH sequences: it contains
the usual half-cystines and 20 of 22 residues found in nearly
all VH sequences so far determined (Fig. 2); the two differences
are conservative replacements (Thr for Ser at position 25;
Leu for Val at position 114). The switch from variable to
constant regions has been established at position 115-116 for
human yyl chains (4, 5), and it may occur at the corresponding
point in A heavy chains (17). H315, a mouse a chain, also has
the Val-Ser-Ser sequence that appears to mark the beginning
of the constant region. If the switch from variable to constant
region really occurs at this point, it is striking that the con-
stant regions of such diverse heavy chains as human Syl,
human MA, and mouse a all begin with the same sequence. This
sequence could be conserved because of constraints imposed
by the putative joining mechanism that is thought to unite
V and C genes (18-20).
The heavy chains of protein 315 and of protein 173 (15) are
the only mouse heavy chains whose sequences have been
extensively determined so far. Each has an unblocked amino-
terminal (Glu or Asp), which is characteristic of human VH
sequences of the VHIII subgroup (21-23), and it has been
suggested that this subgroup may be the predominant one
in some nonprimate species (24). However, the sequences of
VH173 and VH315 differ markedly; the two are only 40% ho-
mologous and they differ by at least two sequence gaps (Fig.
2). VH315 and VH173 are thus likely to represent different
subgroups in the mouse and, therefore, different germ-line
genes. Moreover, both VH315 and VH173 differ significantly
in sequence from the human VHIII regions, and VH315 has as
much overall homology with a representative member of the
human VHII subgroup as with one from the VHIII subgroup.
Hence, not all unblocked heavy chains in the mouse correspond
to the human VHIII subgroup. It is possible that diversity of
VH sequences in the mouse may be as pronounced as the
diversity in the mouse Vk family and in the human Vk, VX,
VH families (25-28) rather than being restricted as in mouse
V> (29).
In view of protein 315's ligand-binding activity, comparison
of its VH and VL segments is of particular interest (Fig. 3).
When these regions are aligned according to the method of
Fitch (30), about 33% homology is evident, in contrast to the
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somewhat lower frequency of identities in VH and VL se-
quences of protein Eu (23%) or of protein Ou (28%) (4, 17).
It is only for three proteins (Eu, Ou, 315) that both VH and
VL are known, and it is thus too soon to know the range of
VH-VL sequence identities in chains from the same molecules
or the significance of these homologies. Because all mouse X
chains, including protein 315, have remarkably similar V-
region sequences (29), VH315 shows essentially the same
homology with the V regions of other mouse X chains, e.g.,
protein 104 (31); but it is less similar to V segments of mouse
k and of human k and X chains (25-28% homology).
The homologous histidines at position 102 in the protein-
315 chains may prove to be particularly interesting. Histidines
are notably infrequent in variable regions (4), but in protein
315 they occur not only at homolegous positions of VH and VL,
but in the V-region sector that is subject to most variation in
immunoglobulin chains (following Cys 96; see refs. 28 and
23). It is possible that these histidine residues interact with
specifically bound ligands (2,4-Dnp and 2,4,6-Tnp groups).
One of the other cyanogen bromide fragments, CN5, was
identified as the carboxy terminus of the heavy chain. It is
the only fragment lacking homoserine: its carboxy-terminal
residue is tyrosine, which is the same as that of intact H315.
The sequence of this fragment is shown in Fig. 4.
IgA has been detected so far only in mammals and in birds,
while the phylogenetically antecedent amphibia have IgG-
like and IgM-like proteins, and the lowest vertebrates
(sharks) seem to have only IgM-like molecules (32, 33). It
has therefore been suggested that by duplication the gene for
ju gave rise to genes for -y and then, relatively recently, for a
(a, x2 )
(Y2ask)
(Y1 sk 9VH IT)
(ii ,kVHII)
(y1 ,k ,VHI)
(aX2)
(Y2ak)
(Y ,k ,VHIII)
(ylsk,VHI)
(a,X2)
(Y2a ,k)
(ylskVHIII)(p,kVHII)
(ylk$VHI)
D V Q
E V K
Z V Q
Z V T
Z V Q
S G
R Y
R Y
T S
R S
L Q
L L
L V
_ T
L V
Y F
W M
T I
R M
A I
6o
- (Y.G)B
N Y - T
H Y - A
F Y W S
NY - A
10
E S G P G L V
E _ G P L V
Q S G G G V V
E S G P A L V
Q STG A E V K
K P
Q L
Q P
K P
K P
20
S Q S L S L I
G G S L K LE
G R S L R L '
K Q P L T L 9
G S S V K V C
ho
K N - W I R Q F P G N K L E W L G
S - -WVRTQAPG~K'GLEW I G
H - - W V E Q A P G K G L E W V A
R V S W I R RP P G K A L E W L A
I - - W V R QA P G Q G LE W M G
P S
P S
D S
T S
Q K
L K
L K
V N
L R
F Q
N R V
D K F
G R F
T R L
G R V
70
S I T R D
I I S R N
T T S R N
S I S K N
T I T A D
T S
D A
D S
D S
E S
E N Q
KN T
K N T
K N Q
T N T
T C S V
S C A-A
S C'A A
r C T F
3 C K A
50
F I
E I
V M
R I
G I
K Y
D P
S Y
V P
80
F F L K
L Y L Q
L Y L N
V V L I
A Y M E
T G Y
S G F
S _ F
S G F
S G G
D G S B -
N S S T I
B G B B K
B B B D K
M F G P P
L D
M S
M N
M I
L S
(a,X2)
(y2a ,k)
(yi ,k ,VHIII)
(p1,kVHII)
(ylk,VHI)
90
(T.Z.B)T A T Y Y
S E D TA LY Y
P Z _T;A VYY
P V _ T A T YY
S E _ TAF Y F
100
C A G D N D H
CAER S P Y Y
CAER I R D T
CAE R V V N S
C A G G Y G I
L Y
A M
A M
V M
Y S
- - - F D Y W
F - - - - - - F A H W
A G Y Y Y Y Y M D V W
- - - - - - - P E E Y
(a,X2 )
(Yl ,k ,VHIII)
(yl3,kVHII)
(y1,k,VHI )
G T
G T
G T
G -
120
T L T V S S E S A R
L V T V S S A S T K
T VYTV S S G 'EA S
L V T V SFSA S T K
130
N P T I Y P L(ALV,Z,K,S ,B, Z,S,G)P
A P T L F P L V S C E N S (D,P,S ,S,T)
G PSV F P LAPS S KS TS G G T
(a, X2)
(U,kpVHII)
(ylgkVHI)
14o
V I
V A
A A
150
I G C L I H B Y F PP(S ,G)- T M
V C L A Z DY F L P D S I TF
L GE C L V K -D Y F P E P V IF V
FIG. 2. Amino-acid sequence of the amino-terminal cyanogen bromide fragment (CN2) from the heavy chain of protein 315, compared
with the corresponding sequences of another mouse and several human chains. Residues are numbered according to the sequence in pro-
tein Eu. Gaps are introduced to maximize homologies; residues identical in all these sequences are underlined. The vertical line between
positions 115 and 116 marks the probable transition from V to C region. References are: mouse protein 173 (15); human proteins Nie (16),
Ou (17, 35), Eu (4, 5). Abbreviations are from Atlas of Amino Acid Sequence and Structure, Dayhoff, M., ed. (National Biomedical
Research Foundation, Silver Spring, Md.), Vol. 5 (1972).
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FIG. 3. Comparison of the variable regions of heavy and light chains (VH and VL) of protein 315. The VH sequence is from Fig. 2, this
paper; the VL sequence is from ref. 7. The sequences are aligned according to Fitch (30). Boxed positions (33% of the total) are identical
(28% are definite and 5% are probably identical). Numbering is according to protein Eu (see Fig. 1). (*) residues labeled specifically in
the intact protein by [ 4C]bromoacetyl Dnp affinity-labeling reagents (Tyr 34 of VL and Lys 52 of VH, see ref. 13).
Mouse a Met-Ser-Glx-Gly-Asx-Gly-Ile-Cys-Tyr
Human a Met-Ala-Glu-Val-Asp-Gly-Thr-Cys-Tyr
Human u Met-Ser-Asx-Thr-Ala-Gly-Thr-Cys-Tyr
Human Y1 Gln-Lys-Ser-Leu-Ser-Leu-Ser-Pro-Gly
FIG. 4. Comparison of the carboxy-terminal nonapeptides of
the heavy chains of protein 315 (a), human a, human ,u, and
human yi (5, 34-36).
(34). This proposal is in accord with the striking similarity
between the carboxy-terminal sequences of human a, mouse
a, and human A chains (Fig. 4); five of nine residues are
identical. At the beginning of the constant region, however, the
protein-315 a chain is hardly more homologous with human ,A
than with human -y chains (Fig. 1) and, overall, a and -y are
alike in that both are shorter by about one constant-region
domain (about 110 residues) than ,u chains. Hence contem-
porary a and Sy might have arisen from a common precursor
(derived from ,u), with conservation of the carboxy-terminal
sequence in a for a specific biologic function. Additional se-
quence data on the constant region of H315 may help clarify
the evolution of immunoglobulin chains.
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